
Sign up to save your podcasts
Or


“Patients are waiting…”
Those simple but profound words from Dr. Steve St. Onge set the tone for this conversation, and for why this work matters so deeply.
Science has always fascinated me. I often joke that I’m not smart enough to be a scientist, but I have endless respect for the people who are, especially those who can take incredibly complex ideas and explain them in a way the rest of us can truly understand. This is why I know you're going to love my conversation with Dr. St. Onge.
Steve is the Chief Business Officer at Clarametyx. Dr. St. Onge is a PharmD and MBA with more than 15 years of experience spanning clinical care, medical affairs, and leadership in biotechnology. What stands out most about Steve isn’t just his impressive résumé, it’s his ability to clearly explain the science, the strategy, and, most importantly, the urgency behind the work Clarametyx is doing.
I first met Steve in person at the North American Cystic Fibrosis Conference (NACFC) in Seattle, where we had the opportunity to really connect and talk about Clarametyx’s approach. Their work focuses on targeting biofilm-driven inflammation and progressive lung damage, an area of significant unmet need for people living with chronic respiratory diseases, including cystic fibrosis. In this conversation, Steve breaks down what biofilms are, why they’re so difficult to treat, and how Clarametyx is thinking differently about tackling the inflammation and lung damage they cause.
We also talk about the long road of drug development, the responsibility that comes with working in rare disease, and why the phrase “patients are waiting” isn’t just a saying, it’s a call to action. This episode is an honest, accessible, and hopeful look at science in motion, and at the people behind the research who are driven by the patients counting on progress.
If you’ve ever wanted a clearer understanding of how innovative science moves from idea to impact—and why time matters so much, his is a conversation you won’t want to miss.
Please like, subscribe, and comment on our podcasts!
Please consider making a donation: https://thebonnellfoundation.org/donate/
The Bonnell Foundation website:https://thebonnellfoundation.org
Email us at: [email protected]
Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featured
Thanks to our sponsors:
Vertex: https://www.vrtx.com
Viatris: https://www.viatris.com/en
Read us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-page
Watch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y
By Laura Bonnell4.7
2020 ratings
“Patients are waiting…”
Those simple but profound words from Dr. Steve St. Onge set the tone for this conversation, and for why this work matters so deeply.
Science has always fascinated me. I often joke that I’m not smart enough to be a scientist, but I have endless respect for the people who are, especially those who can take incredibly complex ideas and explain them in a way the rest of us can truly understand. This is why I know you're going to love my conversation with Dr. St. Onge.
Steve is the Chief Business Officer at Clarametyx. Dr. St. Onge is a PharmD and MBA with more than 15 years of experience spanning clinical care, medical affairs, and leadership in biotechnology. What stands out most about Steve isn’t just his impressive résumé, it’s his ability to clearly explain the science, the strategy, and, most importantly, the urgency behind the work Clarametyx is doing.
I first met Steve in person at the North American Cystic Fibrosis Conference (NACFC) in Seattle, where we had the opportunity to really connect and talk about Clarametyx’s approach. Their work focuses on targeting biofilm-driven inflammation and progressive lung damage, an area of significant unmet need for people living with chronic respiratory diseases, including cystic fibrosis. In this conversation, Steve breaks down what biofilms are, why they’re so difficult to treat, and how Clarametyx is thinking differently about tackling the inflammation and lung damage they cause.
We also talk about the long road of drug development, the responsibility that comes with working in rare disease, and why the phrase “patients are waiting” isn’t just a saying, it’s a call to action. This episode is an honest, accessible, and hopeful look at science in motion, and at the people behind the research who are driven by the patients counting on progress.
If you’ve ever wanted a clearer understanding of how innovative science moves from idea to impact—and why time matters so much, his is a conversation you won’t want to miss.
Please like, subscribe, and comment on our podcasts!
Please consider making a donation: https://thebonnellfoundation.org/donate/
The Bonnell Foundation website:https://thebonnellfoundation.org
Email us at: [email protected]
Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featured
Thanks to our sponsors:
Vertex: https://www.vrtx.com
Viatris: https://www.viatris.com/en
Read us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-page
Watch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

98 Listeners

58,485 Listeners

4,558 Listeners